




Development of Targeted Extracellular Vesicles Technology

PI : Prof. Thai-Yen Ling
Department and Graduate Institute of Pharmacology,
National Taiwan University.

Experience:

[https://www.mc.ntu.edu.tw/pharmacology/Vcard.action?q_type=-1
&q_itemCode=451](https://www.mc.ntu.edu.tw/pharmacology/Vcard.action?q_type=-1&q_itemCode=451)



Market Needs: Development of cell therapy products, optimization of human cell therapy products delivery systems.

Our Technology: A specific recombinant protein is engineered to conjugate with extracellular vesicles derived from cells. This modification process leads to the creation of extracellular vesicles equipped with targeting abilities. As a result, these vesicles can precisely transport therapeutically effective payloads to particular tissues or organs for the purpose of repair.

Strength: Enhancing the efficiency of human cell therapy product delivery systems aims to improve therapeutic effectiveness while minimizing off-target effects of the extracellular vesicles themselves.

Competing Products: Targeted exosomes for cancer cells

Intellectual Properties:

- (1) With two decades of experience in cell therapy, our research team is dedicated to developing cell therapy products to treat various acute and severe conditions.
- (2) Our research team holds a patent for serum-free cultured stem cells (Application Number: [100134890]).

Contact (do not need to fill out):

Center for Industry-Academia Collaboration, NTU

Tel: 02-3366-9945, E-mail: ordiac@ntu.edu.tw